Showing posts with label health insurance. Show all posts
Showing posts with label health insurance. Show all posts

Saturday, 14 February 2026

Health Economics

 




Here is a summary of the video from the 0:00 to 15:00 minute mark:

0:00 - 0:50 Introduction
Professor Gruber introduces the final lecture as a different kind of class. He will apply the economic tools learned throughout the semester to the real-world topic of health care policy, drawing on his 25 years of experience in the field.

0:51 - 3:46 Background: The US Health Care Problem

  • High Spending: The US spends far more on health care than any other developed nation—about 17.5% of its GDP (nearly $10,000 per person). This is roughly double what many European countries spend.

  • Mixed Outcomes: Despite this spending, health outcomes are unequal. The "haves" (well-insured) get the best care in the world, evidenced by a million people coming to the US for treatment. The "have-nots" get some of the worst care. For example, a Black baby is twice as likely to die in its first year as a white baby, a rate worse than Barbados.

  • The Two Fundamental Problems: The US faces two core issues: spending is too high, and access to care is too unequal. The lecture will focus on these two aspects.

3:47 - 12:27 The Access Problem

  • The Uninsured: Before 2014, about 50 million Americans were uninsured.

  • Market Failure, Not Just Choice: The fact people are uninsured is a policy concern due to market failure (adverse selection) and redistribution (the uninsured are poorer).

  • How Insurance Worked (Pre-ACA):

    • Employer-Sponsored Insurance (60%): Most Americans get insurance through their employer. Insurers prefer large groups because risk is predictable.

    • Individual Market (6%): This market functioned poorly due to adverse selection. Insurers feared only sick people would buy insurance, so they protected themselves through "pre-existing conditions exclusions" (refusing to cover costs related to past illnesses) or "medical underwriting" (denying coverage or charging exorbitant prices to sick individuals). This meant if you were sick, you often couldn't get insurance.

    • Government Insurance (20%): Two main programs: Medicare (for the elderly) and Medicaid (for the poor). These programs offered full coverage without discrimination.

    • The Uninsured (15%): These were typically the "working poor"—people with jobs that don't offer insurance but who earn too much to qualify for Medicaid.

12:28 - 15:00 Historical Reform Attempts and Two Extreme Solutions
For 100 years, efforts to reform health care failed because they were caught between two extreme solutions:

  • Solution 1: Subsidization: Giving money to help people buy insurance. The problem is that it doesn't fix insurers' incentive to avoid sick people and is politically difficult.

  • Solution 2: Single-Payer: A government-run system for everyone (like in Canada). The lecture outlines three major political barriers to this:

    1. Paying for it: It requires a massive, visible tax increase, even though it would replace the "hidden tax" of employer-sponsored insurance (where employers pay lower wages in exchange for providing insurance). People don't believe employers would pass the savings back to them in wages.

    2. Status Quo Bias: People with employer-sponsored insurance are reluctant to give up what they know for an unknown new system, due to loss aversion.

    3. Powerful Lobbying: Health insurance is a massive industry that would fight aggressively to protect its business.


Here is a summary of the video from the 15:00 to 30:00 minute mark:

15:00 - 21:00 The "Three-Legged Stool" Solution
Stuck between the extremes of subsidization and single-payer, economists (including Professor Gruber) developed a new approach, first pioneered in Massachusetts and later becoming the basis for the Affordable Care Act (Obamacare). This "three-legged stool" consists of:

  1. Ban Insurer Discrimination: Insurers are no longer allowed to deny coverage or charge higher prices based on pre-existing conditions. They must offer insurance to everyone at a standard community rate.

  2. The Individual Mandate: If insurers are forced to accept everyone, they will only get sick buyers and go bankrupt. To fix this, everyone is required to purchase insurance. This ensures a balanced pool of both healthy and sick people, allowing insurers to function like a bookie setting odds to guarantee a profit.

  3. Subsidies: A mandate is unfair if people cannot afford insurance. Therefore, the government provides income-related subsidies to make coverage affordable for low-income individuals.

21:00 - 30:30 The Impact and Ongoing Debate on Access

  • Did it work? Yes, it was the largest insurance expansion in American history, covering about 45% of the uninsured nationally (and 2/3 in Massachusetts).

  • Why are people still uninsured? Three main reasons:

    1. The law doesn't apply to undocumented immigrants (about a quarter of the uninsured).

    2. The mandate has exemptions (e.g., for those below the poverty line or for whom insurance is still unaffordable).

    3. The penalty is a tax, and some people prefer to pay it rather than buy insurance.

  • Political Challenge: This three-part solution is more complicated to explain than simple alternatives like "single-payer." While it was a major step forward, it hasn't solved the access problem entirely, leaving an ongoing debate, particularly within the Democratic party, about whether to push for single-payer.

30:30 - 45:00 The Cost Problem

  • Two Contradictory Facts:

    1. It's been worth it: Health care spending has quadrupled since 1950, but the improvements in health outcomes (e.g., lower infant mortality, better heart attack and knee surgery treatments) have been economically worth the cost.

    2. It's incredibly wasteful: An estimated one-third of all health care spending does nothing to improve health.

  • The Core Challenge: The productive 2/3 of spending is so valuable that it makes the overall rise in costs seem worthwhile, but the unproductive 1/3 represents massive waste. The problem is that while we can identify waste in hindsight, it is extremely difficult to prospectively know which treatments will be effective and which will be wasteful.

  • Two Potential Solutions to Control Costs:

    1. The Regulatory Path (European Model): Direct government control over the health care system through:

      • Technological Regulation: Rationing certain procedures (e.g., denying kidney transplants to people over 75).

      • Supply Regulation: Limiting the number of doctors, hospitals, and machines (e.g., Canada has far fewer MRI machines).

      • Price Regulation: The government sets the prices for medical services. This is the most important method. The US is unique in letting the free market set most prices, which fails due to market imperfections like lack of information (you can't shop for a heart attack) and imperfect competition (monopoly hospitals or prestigious hospitals charging far more).

    2. The Incentives Route (ACOs): This approach, a key part of Obamacare, creates "Accountable Care Organizations" (ACOs)—groups of doctors and hospitals that work together. Instead of paying for each service, the government pays them a flat fee per patient to manage all of that person's care. The idea is to give them an incentive to be efficient. However, this approach has not worked well in practice, as providers struggle to figure out how to effectively manage care and costs within this system.

Here is a summary of the video from the 30:00 minute mark to the end (46:00):

30:30 - 41:00 The Cost Problem (Continued)

  • Two Potential Solutions (Continued):

    • The Regulatory Path (European Model): This involves direct government control through:

      • Technological Regulation: Rationing certain procedures (e.g., denying kidney transplants based on age).

      • Supply Regulation: Limiting the number of doctors, hospitals, and machines (e.g., Canada has far fewer MRI machines, leading to long waits).

      • Price Regulation: The government sets the prices for medical services. This is the most important method. The US is unique in letting the free market set most private insurance prices, which fails due to market imperfections like lack of information (you can't shop for a heart attack) and imperfect competition (monopoly hospitals or prestigious hospitals like MGH charging far more due to a "reputational monopoly"). While Medicare successfully uses price regulation, applying it universally is politically difficult and has failed in the past (e.g., state-level attempts in the 1970s).

    • The Incentives Route (ACOs): This approach, a key part of Obamacare, creates "Accountable Care Organizations" (ACOs)—groups of doctors and hospitals that work together to provide all of a patient's care. Instead of paying for each service, the government pays them a flat fee per patient to manage all of that person's care. The goal is to give them an incentive to be efficient and control costs. However, this approach has not worked well in practice, as providers struggle to figure out how to effectively manage care and costs within this system.

  • Why This Matters: Health care costs are the single most important government fiscal problem. The US faces a long-term deficit of roughly $75 trillion, and $70 trillion of that is driven by health care costs. Controlling costs is as critical an issue for the future as climate change.

41:00 - 46:00 Course Conclusion

  • The Goal of the Course: Professor Gruber explains that the purpose of 14.01 is not to memorize formulas, but to:

    1. Spark an interest in economics.

    2. Make students more educated consumers of news and policy, especially in an era where facts and the scientific method are under attack.

  • The Economist's Job: He concludes with a joke about a doctor, a priest, and an economist who are rude to a slow, blind golfer. While the doctor and priest pledge charitable acts to atone, the economist asks, "If he's blind, why doesn't he just play at night?" The point is that the economist's job is to be "annoying"—to question basic assumptions, find logical flaws in arguments, and think critically about problems to find responsible solutions.

Thursday, 12 February 2026

Health Insurance Reset: Base MHIT plan by Bank Negara Malaysia

 





















# Base MHIT plan by Bank Negara Malaysia – a step in the right direction


Last month, Bank Negara Malaysia released a White Paper on the proposed Base MHIT (Medical and Health Insurance/Takaful) Plan as part of the RESET strategy. RESET is a private healthcare reform framework led by the Ministry of Finance (MoF), Ministry of Health (MoH) and Bank Negara to tackle rising medical cost inflation and improve affordability, conceptualised in the aftermath of the public uproar over steep premium hikes in late 2024.

Our quick take on the base MHIT plan? It is a step in the right direction, addressing some, if not all, of the most pressing issues (finer details still to be announced).

---

## What is the Base MHIT Plan?

The base MHIT plan is designed to be the lowest denominator product — a standalone medical protection plan that balances medical coverage with affordability. The plan caps the annual policy limit at RM100,000, with standardised benefits that cover the costs associated with common complex admissions in private hospitals.

The table below shows a simple comparison between the base MHIT plan and a typical medical insurance policy in the market today:



















| Target group | Ages 21–35 | General |


The premium for the base MHIT plan is much lower because of its lower claim limit and benefits.

Remember our “Airline model” framework for the insurance industry (“High cost of private healthcare — who is responsible and how to mitigate?” [The Take, March 3, 2025]), where there is a basic package (economy class) for the masses and premium packages (business and first class) for those who can afford to pay more? Well, this is the economy class plan.














---

## Why This Makes Sense

As we wrote previously, not everyone needs an “all-in” unlimited claims policy that must necessarily come at higher premiums. Based on statistics, **99% of medical claims are below RM55,225** with the median claim being only **RM5,695**. In other words, RM100,000 is more than sufficient to cover most instances, save for the 1% cases of highly complex and costly treatments that can be managed within the public healthcare system.

Its design as a standalone MHIT product — rather than the typical investment-linked medical riders — makes it less risky, more transparent and simpler for consumers to understand.

For those who prefer to have the choice of additional benefits (such as critical illness and accidental death payouts and investment), treatment options, better non-medical services and so on — and can afford to pay higher premiums — they can opt for the “business” and “first class” MHIT plans currently offered by insurers.

**The point is that this base MHIT plan gives consumers a choice** — to pay for the basic insurance coverage or pay extra for more “frills”.

---

## Why Regulatory Intervention Is Necessary

It is highly unlikely that insurers will voluntarily offer and promote a basic plan with lower premiums — they are profit-maximising private entities. Indeed, **70% of all policies are currently investment-linked**. Insurers and agents market these plans more aggressively, as they come with higher premiums, and bundle all the “bells and whistles” to create a perception of value for money.

Since the base MHIT plan is the **lowest-denominator product** to be offered by all insurers, it means there will be **volume**. In actuarial mathematics, volume matters: a larger insured pool (risk pooling improves statistical predictability) means a lower cost per unit. Therefore, **the government is right to step in** — by mandating that all insurers offer this base MHIT plan alongside their own plans — to enable a lower sustainable cost policy.

---

## Affordability and Sustainability

It is crucial that consumers understand that **the best insurance policy is not the one with the most benefits, but one they can sustainably afford for life**, bearing in mind that premiums will continue to rise with medical cost inflation.

In addition, knowing their policy has a lower limit will instil discipline in patients when seeking treatments. They would be more cautious and make more prudent healthcare decisions to preserve their benefits for future needs.

---

## Co-payment: Encouraging Discipline and Responsibility

The base MHIT plan also includes **mandatory co-payment** — requiring the policyholder to bear a portion of the total medical bill before insurance claims kick in. This is another feature we have previously highlighted as important to minimise the **“buffet syndrome”** that is driving up medical healthcare costs for everyone (the individual benefits while all policyholders share the cost).

The co-payment amount is structured into two tiers, depending on the hospital (lists to be announced later):

- **Tier-1 hospitals**: Deductible cap of RM500 per disability

- **Tier-2 hospitals**: Additional co-share of 20% of the hospital bill, capped at RM3,000

**The point is**: when policyholders have to share the costs, they will be more inclined to weigh the necessity and value of each medical decision, as there is now a direct financial implication for every choice made. Co-payment pushes patients to be **active participants** in managing their healthcare expenses.

---

## Standard-Plus Base MHIT Plan

Bank Negara has also proposed a **standard-plus-base MHIT plan**, which has:

- Higher annual limit: **RM300,000**

- Higher co-payment (deductibles): **RM10,000 to RM15,000**

- Cheaper premiums: **15% to 45% lower** than the base plan

Why does this work? **The higher the co-payment, the less likely policyholders will “overindulge”** on medical and hospitalisation care. This is likely to lower the total payout by insurance companies over time.

**Obviously, this is not good news for private hospitals.**

---

## Overall Assessment: Constructive but Not a Silver Bullet

In short, we think the base MHIT plan is **constructive**.

Yes, it does not address all the problems plaguing our public healthcare system and escalating medical costs. It is not meant to, on its own. It is part of the **multi-pronged RESET strategy**. We await more initiatives under RESET, such as **DRG (Diagnosis-Related Groups)** to be implemented, whose features will gradually be worked into this base MHIT plan.

What it does is:

- Give more people **optionality**

- Encourage better-informed medical decisions via **co-payment**

In fact, the base MHIT plan **may not necessarily be less profitable for insurers**, as it should lower cases of overtreatment (which drives up medical cost inflation and claims) and policyholders now share part of the cost.

If managed well, we can foresee that the base MHIT plan will be **beneficial to the healthcare and insurance industries in the long run**.

---

## Who Is This For?

Given that the base MHIT plan is the lowest-denominator product, **it will expand affordability to more middle-income households** — those who can afford private healthcare. 

**Note: It is not a social insurance scheme meant for everyone.**

---

## A Watershed Moment: Lessons from 2024

The shocking 2024 premium hikes were a watershed, **shattering the illusion** that buying insurance young, when premiums are low, will protect one through life.

People now understand that **premiums are not fixed for life** and, therefore, one must select a policy that will continue to be affordable when premiums inevitably rise with healthcare cost inflation. We do not want to be caught again with the impossible choice of:

- Keeping a policy we can barely afford, or

- Giving it up and risking massive hospital bills should the unforeseen happen

To be sure, **premiums for the base MHIT plan are not fixed either**. But they are **set by the authorities** (presumably Bank Negara, based on actuarial principles), as are the periodic reviews — which should translate into a **higher level of governance and oversight**.

Coupled with lower claim limits, co-payment, DRG, standardisation and the fact that the plan is **not investment-linked**, future premiums are expected to be **more stable and predictable**.

---

## Our Main Concern: EPF Withdrawals

**Our main concern** is the proposal to allow people to pay for the premium with their **Employees Provident Fund (EPF) savings**.

The authorities have time and again warned that **Malaysians do not save enough for retirement** as it is. Allowing yet another route for members to withdraw from already insufficient savings is **inexplicable**.

**EPF withdrawals should be allowed only for emergencies and in old age.**

As Bank Negara has stressed, the base MHIT plan is designed for **those who can afford private healthcare**. If they cannot afford the premium for this economy class plan, then they would in all likelihood be **better off going to public hospitals**.

---

## A Better Approach: Learning from Singapore

This concept of co-payment and responsibility should be expanded.

As an example, **Singapore** has two schemes:

1. **Matched Retirement Savings Scheme**

2. **Matched Medisave Scheme**

These help eligible Singaporeans boost their retirement and healthcare savings (which will be used to pay for insurance premiums and hospital bills). In essence, the government provides **matching grants (with limits)** for every dollar top-up to their Retirement/Special Accounts and Medisave Accounts, to **encourage the saving culture**.

**This is far better than simply giving poorly designed cash handouts.** When things are given for free, they lose value very quickly. Worse, it discourages personal responsibility.

---

## Conclusion

The base MHIT plan is a **meaningful, targeted reform** that introduces choice, affordability, and discipline into Malaysia's private healthcare and insurance ecosystem. It is not a complete fix — but it is a solid start.

Wednesday, 13 May 2015

Why the Rich Don’t Buy Insurance and Unit Trusts

Not all insurance products and unit trusts are created equal. The writer wonders why most people at the top don’t believe in them.

Why did Warren Buffet buy an insurance company?
Because _______________.
I just returned from a harrowing experience at this local insurance company and a morning of blank faces and passive responses to my torrent of questions.
Why have I been paying S$7,000 per year and getting all these optimistic updates on fund performance, and after 10 years I end up losing more than 40 percent of my premiums?
Investment-linked what?
You see, I had blindly signed the papers when my mom suggested I buy a bunch of investment-linked products over a decade ago, and had paid scant attention to it until urged by an insurance adviser recently.
The realisation that I have been paying very, very expensive premiums over 10 years does not sit well with me and some introspection was required.
That amount that I had paid could have well gone into a life policy such as a universal life option, buying me the same coverage for a fixed payment with loan of 70 percent.
If we assume that an annual universal life premium of S$120,000 buys S$1 million cover for someone aged 30, my paid premiums could have gone to buying whole life coverage until I was 110 instead! (Note: This is probably for international insurance firms and not the local companies that insist on ripping folks off with their simply exorbitant premiums that they force some local banks to fund)
The blank faced staff gave me a scornful look and said if I continued paying I would reap the rewards from it too! Yes, if I had an IQ of 50 maybe.
If I continue paying another 10 years, I would perhaps break even.
Why don’t the rich folks buy these products? Why don’t the private banks sell unit trusts?
Why don't rich people buy insurance or unit trusts
Because these are the black box priced deals that the public has no chance of fighting against. No transparency and no restitution (don’t even think of going to court).
Private bankers themselves only ever buy term life and medical policies leaving the investment bit out. Investments are separate. And all these articles in the papers telling people that insurance is the way to go for retirement. I just recently discovered that “financial planner” is just another word for insurance agent.
It makes me worried.
Because Warren Buffet knows how profitable it is.


https://www.drwealth.com/2014/12/22/why-the-rich-dont-buy-insurance-and-unit-trusts/?utm_medium=DISPLAY&utm_source=OUTBRAIN&utm_campaign=INVMT

Wednesday, 27 March 2013

Singapore Medical Insurance Programme - MediShield


Reforming MediShield to be truly national ― Jeremy Lim

MARCH 27, 2013
MARCH 27 ― Every now and then, Singaporeans come across a media report of a medical bill in the hundreds of thousands of dollars, and everyone seems to know someone struggling financially after a prolonged illness.
In fact, the late Dr Balaji Sadasivan, previously a junior minister in the Health Ministry, while undergoing treatment for cancer commented: “Cancer treatment can be very, very expensive. This is something our health system will have to deal with. It is not surprising if some patients have to sell their house (sic).”
In dealing with the financials of catastrophic illness, Singaporeans are likely most concerned about two issues: The uncertainty of illness severity with an attendant massive hospital bill, and their share of the bill.
On the former, Health Minister Gan Kim Yong has correctly identified that expanding risk pooling is fundamental.
It does not make sense for every Singaporean to try and save for a hospitalisation episode that may never materialise (half of all heart-related deaths are sudden); and besides, most Singaporeans will never be able to save enough to pay fully for a complex and long-drawn illness.
MediShield is the bedrock insurance programme intended to protect against the financial consequences of medical catastrophes. It is the only health insurance scheme created by an Act of Parliament and must be national.
However, MediShield has three limitations that prevent it from being truly national: Exclusion of pre-existing conditions from coverage, non-eligibility upon reaching 90 years of age; and sharp premium increases with age.
How can we revamp MediShield to assure that it is truly inclusive or national and covers every Singaporean?
Three changes are worth exploring. Firstly, expand MediShield to include all Singaporeans regardless of age or pre-existing illnesses.
This is a monumental decision and truly fundamental as it reframes MediShield from being a scheme run on commercial principles (albeit as a non-profit scheme), to one that is founded on social principles.
The current premium calculations are in age bands, excluding Singaporeans with pre-existing illnesses. For a national programme, it is preferable to spread risk across all age groups and all risk groups.
This would result in younger and healthier policy holders paying more, but would prevent premiums for the elderly (who have healthcare bills four times larger than their younger counterparts) from skyrocketing — and, just as importantly, enabling those with prior cancer, heart disease and the like to have affordable insurance.
Secondly, ensure all Singaporeans can afford to pay the premiums. Premiums may still be higher for the very elderly or those with substantial pre-existing illnesses, and government funding for those who cannot afford to pay their own premiums has to come in.
Thirdly, limit the individual’s risk of medical bankruptcy by imposing a cap on what patients have to pay as their share of the total bill. How this quantum is worked out needs to be transparent, though.
The cap will need to be means-tested in keeping with the government’s philosophy of targeting subsidies, but patients need to know before the fact how the cap is determined and what they are expected to pay.
A point to note: Setting caps on what patients pay does not remove the financial risks in and of themselves. It just means someone else — in this case, the government — has to bear the risk. This will have downstream consequences: The government assuming the risks really means taxpayers carry the can.
Social activists advocating for “peace of mind” for all are really asking for the government to do more AND for taxpayers to fund these measures. Is this a price Singaporeans are prepared to pay for a better Singapore? I certainly hope so.
Minister Gan also highlighted the risks of over-servicing and over-consumption. These are genuine concerns. It would be naive to depend on the “nobility” of individual healthcare professionals who are paid at least in part on a “fee-for-service” model, and equally naive to expect patients to deliberately constrain themselves for the good of society.
What can be done then? Some suggestions build on self-regulation as a professional community, a privilege society extends to doctors.
The Singapore Medical Council is the watchdog for professional misconduct and egregious ethical breaches but what about overall clinical standards of practice? Singapore has a College of Family Physicians for general practitioners and family physicians, and an Academy of Medicine for specialists. These professional bodies can step up to the plate.
Developing clinical practice guidelines and coupling rigorous auditing processes to them to identify errant over-servicing doctors would be a good start.
The government’s electronic medical records system has been in the works for almost a decade now and when fully mature, can enable audits and recognition of negative outliers.
Public hospitals already have departmental structures where doctors in the same speciality peer-review each other’s cases, appropriateness of treatment and outcomes.
These could be built upon by government mandate enabling the college and academy to take these governance practices nationally.
Robust audits will be necessary to assure the government that risks of abuse of insurance schemes can be mitigated, and these can be built up progressively.
The challenges are formidable but the reward, a truly national MediShield makes it worthwhile.
On a trip to Taiwan last year, a young Taiwanese remarked to me: “The NHI (Taiwan’s National Health Insurance) makes me proud to be Taiwanese!” Years from now, what will Singaporeans say? ― Today
* Jeremy Lim has held senior executive positions in both the public and private healthcare sectors. He is writing a book on the Singapore health system.

http://www.themalaysianinsider.com/sideviews/article/reforming-medishield-to-be-truly-national-jeremy-lim/

Saturday, 23 June 2012

Investor's Checklist: Health Care


Developing drugs is time-consuming, costly, and there are no guarantees of success.  Look for companies with long patent lives and full pipelines to spread the development risk.

Drug companies whose products target large patient populations or significant unmet needs have a better chance of paying off.

Make sure you have a big margin of safety for pharmaceutical companies with mega blockbuster drugs that make up a large percentage of sales.  Any unexpected development can send cash flow, and the stock price, reeling.

Unless you have a deep understanding of the technology, don't invest in biotech startups.  Payoffs could be large, but the cash flows are so far out and uncertain that it's easier to lose your shirt than win big.

Don't overlook the medical device industry, which is full of firms with wide economic moats.

Cash is king for firms that rely on development (pharmaceuticals, biotechnology, and medical devices).  Make sure firms have enough cash or cash from operations to get through the next development cycle.

Keep an eye on the government.  Any drastic changes in Medicare/Medicaid spending or regulatory requirements can have a deep impact on pricing throughout the sector.

Managed care organizations that spread risk - whether through a high mix of fee-based business, product diversification, strong underwriting, or minimal government accounts - will provide more sustainable returns.  


Ref:  The Five Rules for Successful Stock Investing by Pat Dorsey


Read also:
Investor's Checklist: A Guided Tour of the Market...

Friday, 3 February 2012

Hospital patients 'overtreated and overcharged’


Suspicions that five private hospital groups in Britain are operating a money-spinning cartel have prompted an investigation by theCompetition Commission.
The inquiry follows a damning report last month by the Office of Fair Trading (OFT) that accused hospitals and surgeons of not publishing meaningful data as to their success rates.
It explained that without information such as infection rates it was impossible for patients and GPs to assess quality – a clear suppression of competition.
The OFT also alleged that the hospital groups made inflexible pricing arrangements with insurers. The aim of this was to exclude new hospital groups from breaking in to local provision.
Private medical insurers have long claimed that some private consultants routinely put their bank balances before their patients’ needs. They welcomed the decision of the OFT, following a year-long inquiry, to refer its findings to the watchdog.
Publication of the OFT report highlighted the friction between insurers and providers that has existed for years. Relations further deteriorated when Bupa, the leading medical insurance company in the UK and internationally, said 20p in the pound was being wasted on “inappropriate” surgery.
Dr Natalie-Jane Macdonald, managing director of Bupa Health and Wellbeing, said hospitals in Britain were half-empty. The implication was that they were spinning out treatment cycles and doing unwarranted tests and treatments to stay in business.
What is not disputed is that health insurance premiums have risen by about 10 per cent per annum for several years in the UK – and even more for expats buying international cover.
And while the problem of prolonging treatments, instituting unnecessary tests and putting patients through surgery when better options are overlooked is a big concern in Britain, the picture elsewhere in the world is often worse.
According to the Association of International Medical Insurance Providers (AIMIP), fraud is endemic in parts of the system.
Carl Carter, chairman of the London-based association, said: “We are working among ourselves and with other industry bodies and databases to share information and combat provider fraud and inflated costs – for instance where hospitals are overcharging, charging for treatments they never did, or are overtreating, such as unnecessarily long admission periods.
“Many overseas doctors see an international medical insurance policy as their meal ticket and are keen to charge heavily inflated 'tourist’ rates for much more than they would charge a self-paying or local customer.”
Mr Carter, managing director of IMG Europe, told of a 35-year-old customer who suffered a nosebleed while in Tokyo. He attended a private hospital where the condition was viewed as extremely serious.
Doctors wanted to admit the man for 30 days, but the patient called his insurer. Mr Carter said: “Our medical team liaised with the treating doctor and we agreed to a three-day observation and to review after that.
“It turned out it was a simple case. By coincidence, with the mild concussion he also had high blood pressure and he had scratched inside his nose when he’d been jolted from behind and had fallen over.”
The case highlights the importance of policyholders contacting their insurance company in advance of treatment, emergencies excepted. Routine pre-authorisation is key to curbing abuse.
Mr Carter concluded: “Luckily, the customer followed the instructions on his membership card and all was fine. He made a full recovery and was quickly reunited with his family, and without his policy incurring the bill for 27 unnecessary days of in-patient stay.”
Last year, AxaPPP International linked up with Medix, a global consultancy firm, to give policyholders the chance to take a second opinion before treatment. That is one defence against unnecessary treatment, argues Jonathan Gray, the company’s director of medical services. He also points out that patients may be saved from intrusive and potentially risky diagnostic tests and treatment.
“We recognise that over-treatment is a factor in provision of health care, whether in the UK or abroad. It varies according to the pressure on the providers,” he said. “In the Middle East, where doctors are mostly employed by the hospitals, there’s pressure on them to utilise the hospital facilities. That can lead to unnecessary diagnostics and treatments.”
But similarities occur in all countries. “Particularly with surgeons, a significant proportion of their remuneration is related to the procedures they do. So it’s in their financial interest, if they have the opportunity to justify medically that a procedure takes place, that it goes ahead.”
Mr Gray does not think that unethical practice is systemic in all countries. “We believe it’s a factor in all markets to varying degrees, depending on individual providers or specialists.”
AxaPPP has an anti-fraud team of six people who will investigate a suspect case and, if malpractice is established, will then investigate the whole hospital. Overtreatment is more difficult to detect. A second or third MRI scan in a straightforward case arouses suspicion.
“The key in all this is that additional interventions are not good for health outcomes,” Mr Gray said. The Medix scheme was “about getting people the right treatment for their condition in the right way – it saves the heartache of going through unnecessary procedures.”
One example was a patient who was about to undergo prostate removal, an operation often leading to long-term complications. He was spared surgery when a leading specialist in the US reviewed the tests.
Another insurer to set up an anti-fraud unit recently is InterGlobal. As for Bupa International, it is just as aghast as its UK partner at the relentless rise in premiums.
Sneh Khemka, medical director of Bupa International, points to the apparent readiness of some doctors to perform keyhole knee surgery without clinical need. “Doctors work on a reimbursement basis – the more they do, the more they get paid. In the UK, where we have been looking at the rates of knee arthroscopy, for example, the rate of operations in the privately insured market is almost three times that in the NHS.”
He continued: “One of the postulated reasons is that doctors may be incentivised to do a procedure that they would not otherwise do. That’s the UK situation, but in certain countries outside the UK, I’d say the situation is even more exaggerated.”
While UK doctors are well regulated, the same does not always apply elsewhere. “The standards and the regulations are not there,” he said. “That gives doctors freer licence to practise and that leads to inappropriate intervention.”
Dr Khemka – who has previously voiced a warning that private insurance would become unaffordable if trends continued – added that Bupa, because of its size, had a special responsibility to tackle the problem.
“We don’t want to keep members beholden to ever-rising premiums because hospital groups are charging way above what they should and trying to fill gaps in their capacity by overcharging – which is then directly transferred to individual private members.”
HOW INSURERS POLICE OVERTREATMENT
» Pre-authorisation: It is standard practice for insurers to insist that customers contact them before seeking treatment, except in emergencies. The UK-based body representing global insurers (AIMIP) advises: “The first requirement is clear documentation and membership cards and to always ensure that the insured person gets in touch with their medical insurance provider before getting the treatment or admission.”
» Case management: It is an advantage to have an insurance provider who has in-house medical teams and doctors available as well as a panel of medical specialists available for second opinions. “It’s unlikely that specialists will seek to overtreat if they know someone is monitoring their work,” says AIMIP.
» Information exchange between international insurers so that hospitals known to make fraudulent claims are boycotted.
» Dedicated anti-fraud units set up by insurers.
WHERE ARE THE WORST OFFENDERS?
Insurers mainly point to Asia, South America, the Middle East, Turkey and Spain. But no country is free of medical fraud. Generally, Europe is less infected with the culture of overtreatment because regulation of the medical profession is tighter.
Carl Carter, chairman of AIMIP, says: “Due to very little competition, certain hospitals in China, Hong Kong and elsewhere in Asia are charging exceptionally high rates to expats who are demanding US- or EU-style private hospital facilities when perfectly adequate modern local facilities are also available.
“Among other major offenders are Turkish hospitals and clinics, for trying to admit people when not required, as well as some of the tourist hospitals in Spain for charging 'tourist’ rates to expats.
“It’s not just these areas. In many parts of the world it is common practice for some hospitals and clinics to have a different rate for locals, expats and the tourists.”

http://www.telegraph.co.uk/health/expathealth/9017881/Hospital-patients-overtreated-and-overcharged.html